Effect of Tocopherol and Ascorbic Acid on Neuroinflammation Markers Associated With Neuropeptide Expression in the AgRP/NPY and POMC Pathways in Mexican Population With Obesity

Summary

This clinical trial will determine whether taking ascorbic acid (vitamin C), α-tocopherol (vitamin E), or both together can lower markers of brain inflammation and change the expression of neuropeptides in Mexican adults with obesity.

Main Questions

The study aims to answer:

1. Does vitamin C, vitamin E, or both reduce neuroinflammation?
2. Do these supplements change the expression of neuropeptides linked to obesity? Comparison Groups Researchers will compare the effects of vitamin C alone, vitamin E alone, and the combination of both to see if they improve brain health in people with obesity.

What Participants Will Do

Participants will:

1. Take vitamin C, vitamin E, or both daily, depending on their assigned group
2. Attend clinic visits once every 2 weeks for and tests for checkups and tests for record and report supplement intake so that researchers can monitor and evaluate treatment adherence
3. Provide samples and health information to measure inflammation and neuropeptides , at the beginning of the intervention and at 12 weeks, when the intervention ends.

Conditions

• Obesity (BMI>30)
• Neuroinflammation

Interventions

DIETARY_SUPPLEMENT

Ascorbic acid (Vitamin C)

Participants will receive 1000 mg of ascorbic acid orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of ascorbic acid supplementation in the Biomarkers of neuroinflammation and neuropeptide expression

DIETARY_SUPPLEMENT

tocopherol alpha

Participants will receive 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of tocopherol supplementation in the Biomarkers of neuroinflammation and neuropeptide expression

COMBINATION_PRODUCT

Ascorbic acid + tocopherol alpha

Participants will receive 1000mg of ascorbic acid + 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect ofsupplementation in the Biomarkers of neuroinflammation and neuropeptide expression

Sponsors & Collaborators

• Autonomous University of Morelos

  lead OTHER

Principal Investigators

• Ollin C Martínez Ramírez, Ph.D. · UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

59 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-08-10

Primary Completion

2026-12-30

Completion

2027-08-30

Countries

• Mexico

Study Locations